Researchers have developed a potent inhibitor of the dengue virus, which causes roughly 100 million cases of symptomatic cases of dengue fever annually.
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration with the KU Leuven Rega Institute and the.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today, in collaboration with the KU Leuven Rega Institute and the KU Leuven Centre for Drug Design and Discovery the publication of new preclinical data in the journal Nature showing that an early-stage compound with a novel mechanism of action could potentially treat all serotypes of dengue fever and provide a period of protection against acquiring .